Cdc7-IN-5
Cdc7-IN-5 (compound I-B) is a potent Cdc7 kinase inhibitor extracted from patent WO2019165473A1, compound I-B. Cdc7 is a serine-threonine protein kinase enzyme which is essential for the initiation of DNA replication in the cell cycle[1].
Product Specifications
CAS Number
[1402057-86-6]
UNSPSC
12352005
Target
CDK
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/cdc7-in-5.html
Concentration
10mM
Purity
96.73
Solubility
DMSO : 12.5 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C(C(C/1=O)=C(N2CC3=C(C=CC(OC)=C3)CC2)OC1=C/C4=CNC5=NC=CC=C54)OCC
Molecular Formula
C25H23N3O5
Molecular Weight
445.47
References & Citations
[1]Christian Andrew HASSIG, et al. Methods of treatment of cancer comprising cdc7 inhibitors. WO2019165473A1.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
BDKRB1 (B1 Bradykinin Receptor, BK-1 Receptor, B1R, BRADYB1) discontinued
Human Monoclonal PD-L1 Antibody (sudubrilimab) [Janelia Fluor 635]
